(033) DO PEYRONIE’S DISEASE PATIENTS WITH CONCOMITANT DUPUYTREN’S CONTRACTURES RESPOND BETTER TO INTRALESIONAL INJECTION OF COLLAGENASE CLOSTRIDIUM HISTOLYTICUM?

Abstract

Listen

Translate article

Abstract Introduction Dupuytren's contractures (DC) are prevalent in men with Peyronie's disease (PD). There is, however, limited data regarding the impact of DC on the efficacy of intralesional injection of Collagenase Clostridium Histolyticum (CCH) for the management of PD. Objective This study aimed to examine the demographics of patients undergoing CCH therapy for PD and compare the outcomes between DC and non-DC patients. Methods We conducted a retrospective chart review of PD patients attending a tertiary care men's health center between October 1, 2017 and September 30, 2023. Demographic information, treatment modalities, and outcomes were systematically collected. A comparative analysis was performed between PD patients with and without DC. Results Among the 573 patients in this cohort, 43 with history of DC. Two hundred and ninety-two opted for CCH as first line therapy. One hundred eighty-seven patients had at least 4 cycles of treatment. Of those, 17 patients (9.1%) had a history of DC, and 170 (90.9%) did not. Mean ages were 66.7 ± 5.0 (DC) and 57.1 ± 11.3 years (non-DC), P < 0.001 (table 1). The pre-treatment composite degrees of curvature were 47.5 ± 14.4 (DC) and 43.2 ± 13.4 degrees (non-DC), P = 0.210. Number of injection cycles administered were 4.6 ± 0.9 (DC) and 4.6 ± 1.2 (non-DC), P = 0.904. Post-treatment, the composite degree of improvement was significantly higher in the DC group 29.3 + 12.8 degrees, 63.5 + 27.9 % improvement vs 20.8 + 13.9 degrees, 48.1 + 27.9 % improvement in the non-DC group, with a mean difference of 8.6 + 3.7 degrees (95% CI 1.4, 15.8; P = 0.020), and 15.5 + 7.3% improvement (95% CI 1.1, 29.9; P = 0.036). Conclusions Our study suggests that the concomitant presence of DC is a predictor of better response to intralesional injection of CCH in men with PD. Despite the limited sample size and the retrospective design, these findings merit further exploration. Disclosure No.